Loading
Life sciences · Journal article
Journal of Biomaterials Applications · November 5, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Nanomedicines built on advanced biomaterials are emerging as promising solutions for cancer therapy due to their potential for faster clinical translation. Selecting appropriate animal or in vitro models is critical to accelerating this translation while improving affordability and accessibility. This scoping review examines the preclinical model landscape for Pancreatic Ductal Adenocarcinoma (PDAC), a malignancy projected to become the second leading cause of cancer-related death by 2030. Early diagnosis and timely treatment substantially reduce reliance on surgical intervention and improve survival, underscoring the need for models that support development of early-diagnostic tools and less invasive nanomedicine-based therapies. This review classifies preclinical models ranging from immunocompromised to non-immunocompromised rodents (mice, rats, hamsters) and porcine systems according to their suitability for studying pharmacokinetics/pharmacodynamics (PK/PD) of nanomedicines, and for analyzing mutagenesis, tumor growth, engraftment, metastasis, and tumor heterogeneity. Chemotherapeutic agents and nanodrug delivery systems are compared across these models, with chemically induced rat models identified as particularly robust for PK/PD evaluation. We further assess emerging in vitro organoid models derived from cell lines, primary human tissue, xenografts, and organoid-rodent hybrid systems for their capacity to accelerate drug and nanomedicine screening. Our analysis indicates that in vitro organoid models combined with rat models offer the most efficient platform for demonstrating nanomedicine efficacy, safety, and ability to overcome therapeutic resistance in PDAC. It also highlight opportunities to integrate organoid systems with Artificial Intelligence and Machine Learning ( AI/ML) approaches to further accelerate translational timelines, offering a roadmap for aligning model selection with specific clinical endpoints in future nanomedicine development.